According to @mcuban, scale in healthcare enables regulatory capture as large firms can buy enough companies and generate sufficient profits to influence the rules. Source: @mcuban on X, Nov 28, 2025. He adds that markets need efficiency and asserts healthcare markets have zero efficiency. Source: @mcuban on X, Nov 28, 2025. For traders, his comments flag headline and policy-risk sensitivity for large, consolidation-driven healthcare equities (insurers, PBMs, hospital roll-ups), where perceived regulatory capture could act as a negative sentiment catalyst in valuation screens and positioning. Source: @mcuban on X, Nov 28, 2025. Active strategies may focus on relative strength between mega-cap acquirers and smaller providers during antitrust, pricing, or M&A newsflow that aligns with this critique. Source: @mcuban on X, Nov 28, 2025.

According to @mcuban, the key problem is companies that underpay providers and make care unaffordable by controlling healthcare markets, and he urges focusing pressure on the DOJ to act rather than debating whether healthcare is a right, source: Mark Cuban on X, Nov 28, 2025. For traders, his enforcement-focused message highlights regulatory developments as a potential catalyst; monitor DOJ communications and company disclosures tied to market concentration and pricing practices across U.S. managed care, PBMs, hospital operators, and drug distributors to manage headline risk, source: Mark Cuban on X, Nov 28, 2025. No cryptocurrencies are mentioned in the statement, and no direct crypto market impact is indicated, source: Mark Cuban on X, Nov 28, 2025.

According to Mark Cuban, large PBMs and major drug wholesalers price many fees, rebates, and services as a percentage of a drug’s retail price, so higher retail prices mean higher revenues for intermediaries, source: Mark Cuban on X Nov 26, 2025. For trading context, publicly listed operators of PBMs include CVS Caremark under CVS, Express Scripts under Cigna CI, Optum Rx under UnitedHealth UNH, CarelonRx under Elevance Health ELV, and Humana Pharmacy Solutions under Humana HUM, while the dominant US wholesalers are McKesson MCK, Cardinal Health CAH, and Cencora COR, source: company filings and investor relations disclosures as of 2024. The US Federal Trade Commission is conducting a 6b study into PBM practices and released interim findings in 2024 highlighting concerns around rebates, fees, spread pricing, and market concentration, a regulatory backdrop relevant to assessing pricing model exposure in these tickers, source: US Federal Trade Commission public statements in 2022 and the interim report in 2024.

According to Mark Cuban on Twitter, pharmacy benefit managers (PBMs) manipulate drug prices by controlling formularies and maximizing rebate revenue, restricting Big Pharma from setting their own pricing. Cuban states that three major PBMs negotiate the majority of drug prices, impacting the entire pharmaceutical supply chain (source: Mark Cuban Twitter, June 19, 2025). For traders, this concentration of PBM power creates pricing pressure on pharma stocks and may trigger increased regulatory scrutiny, which could affect pharma sector equities and related healthcare ETFs. Crypto investors should monitor the potential for regulatory spillover, as similar market structure debates could influence tokenized healthcare projects and DeFi protocols focusing on medical data or pharmaceutical payments.